Medical Marijuana in Canada: A Growth Industry

Pharma's Flu Drug Could Be Worth Billions, Analyst Says
Source: Brian Abrahams (09/29/2025)

Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development.

read more >

Biotech Discovers Breakthrough DMD Therapy Opportunity
Source: Dr. Leland Gershell (09/26/2025)

Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc.

read more >

Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Source: Dr. Douglas Loe (09/05/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report.

read more >

Healthcare Firm Targets Alzheimer's With Technology Breakthrough
Source: Streetwise Reports (09/05/2025)

Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need.

read more >

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial
Source: Streetwise Reports (09/03/2025)

Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart.

read more >